ABSTRACT. Epidermal growth factor (EGF) and trans-found in human fetal (6, 11) and adult (12) intestine. In fetal forming growth factor-a (TGF-a) are mitogenic to the rhesus monkey (13) and suckling rabbits (14), EGF stimulates intestinal epithelium. To further clarify their role in the proliferation of the intestinal epithelium. However, in fetal mice developing human fetal gut, their expression was studied (15) and newborn rats (16), it has no effect on DNA synthesis. in fetuses at 15 to 20 wk of gestation. TGF-a mRNA was Therefore, the effects of EGF on small intestinal cell proliferation present throughout the gastrointestinal tract, most abun-and maturation seem to vary with the developmental stage (17). dantly in the duodenum. EGF mRNA could be detected In cultured human fetal jejunal explants, EGF increases lactase only with ribonuclease protection assay and reverse tran-production and decreases DNA synthesis (17). DNA synthesis is scription-polymerase chain reaction analysis. The effect of also diminished by EGF in human fetal colon explants (18). EGF and TGF-a on TGF-a mRNA expression was studied EGF-R binds both EGF and TGF-a. Binding studies with 1251-by culturing explants of fetal jejunum, ileum, and colon for EGF show that in the human fetus EGF-R is present in the 7 d in Leibowitz L-15 medium supplemented with 100 pg/ epithelial cells of both the small intestine and colon from the L of either EGF or TGF-a. EGF receptor-like immuno-12th wk of gestation (19). Immunoreactive EGF-R is detectable reactivity was detected in both the villi and the crypts. In in the villous epithelial cells from the 16th wk of gestation (20). the jejunum, exogenous EGF up-regulated TGF-a mRNA EGF up-regulates TGF-a mRNA in human colon carcinoma 3-fold. However, exogenous TGF-a reduced its own mRNA (2 1) and in rat intestinal epithelial cell lines (22) during 2 to 48 by 40%. No mature 6-kD TGF-a was detected in the h of exposure. However, for a study of intestinal development, a culture medium by Western blotting, but precursor forms longer stimulation time is needed to mimic the in vivo situation of approximately 30 and 68 kD were present. The ileum in utero with continuous passage of amniotic fluid through the and colon did not respond to either growth factor. Besides fetal gut. The present study was undertaken to clarify the expresthe gut, TGF-a was expressed in the gallbladder, salivary sion and role of EGF and TGF-a in the developing human fetal gland, adrenals, brain, kidney, liver, and placenta. The data GI tract. It also explores whether these peptides regulate TGF-a imply an important role for TGF-a and EGF in the devel-mRNA production in long-term organ explant cultures. oping intestine. (Pediatr Res 33: 481-486, 1993) MATERIALS AND METHODS
MATERIALS AND METHODS

Abbreviations
Fetal tissues. Tissues were obtained from prostaglandin-in-EGF, epidermal growth factor duced legal abortions at 15 to 20 wk of gestation. The study was EGF-R, epidermal growth factor receptor approved by the Ethical Committee of the Hospital. Delay from GI, gastrointestinal delivery room to liquid nitrogen or cell culture was 1 h. The TGF-a, transforming growth factor-a gestational age was estimated from the fetal foot length (23). The PCR, polymerase chain reaction intestines were dissected from the surrounding mesentery and AP, alkaline phosphatase stored in liquid nitrogen at -70°C for RNA extraction or further RNase, ribonuclease processed for organ explant cultures. Other tissues (submandibular salivary gland, pancreas, gallbladder, liver, adrenals, kidney, lungs, thyroid gland, brain, cerebellum, spinal cord, skin, testes, femur, and decidua from a 2nd-trimester placenta) were stored similarly. EGF and TGF-a are mitogenic peptides that also inhibit gastric explant cultures. The intestine was divided into jeacid production ( l , 2). In dogs, TGF-a is synthesized by parietal junum, ileum, and colon. These fragments were split longitudicells of the stomach (3). Many GI tumors (4) and cell lines as nally, cut into 3 x 7 mm pieces, and placed in Petr-dishes on as the human (' 1 'ynthesize TGF-a lens papers (24). Explants were cultured overnight in (medium mRNA. Immunoreactive TGF-a has been detected in mucosal Dulbecco~s minimum essential medium-l~% F~~-penicillincells of human fetal (6) and adult (7) gut and in colorectal streptomycin) and starved for 4 h in Leibowitz L-15 medium neoplasia (8) . Rat intestinal epithelial cell line IEC-6 also ex-(Gibco, Paisley, UK) before stimulations with recombinant huPresses TGF-a transcripts and an EGF-R binding substance (9) . man EGF 100 p g /~ (Bachem, Bubendorf, Switzerland) and EGF is present in salivary, gastric, duodenal, pancreatic, and human TGF-a 100 pg/L (Bachem) in Leibowitz Lamniotic fluids (10) . Immunohistochemically, EGF has been medium. ~h~ media were renewed after d 1 of culture and B R Fig. 1 . Southern blots from TGF-a PCR. Reverse transcribed RNA from human fetal (15 to 20 wk of gestation) intact (30 cycles) and cultured (60 cycles) gut ( A ) and other fetal tissues (30 cycles; B) were amplified using TGF-a-specific primers. Autoradiography after Southern transfer and hybridization with a "P-labeled TGF-a cDNA probe showed a single band of 262 bp. On the left is shown a 27 1-bp band from the size marker @XRF174/HaeIII. The cultured intestine was grown in medium without (Co, control) or with supplementation of EGF or TGF-a (100 pg/L both).
RNA derived from A43 1 cells was used as a positive hybridization control for the TGF-u probe (4) . or TGF-u cRNA and 28s or y-actin cDNA probes as described (27) . The filters were washed in 0.1 x SSC (1 x SSC is 0.15 M NaCl and 0.0 15 M sodium citrate) with 0.1 % SDS (three times for 20 min at 65°C for cRNA and at 50°C for cDNA probes) and subjected to autoradiography using Trimax T16 ( 3~, ~e n a n i a , Fig. 2 . RNase protection assay from intact and cultured human fetal Italy) intensifying screens and Hyperfilm MP films (Amersham) gut. Fifty pg of RNA from fractioned intestine (17 wk of gestation) and for to wk at -700C. Northern blots were usually done from 30 pg RNA from cultured intestine were hybridized with a "P-labeled TGF-a cRNA. After RNase treatment, 262-bp-protected fragments were three to six fetuses. Dot blot. Total RNA (2.5 to 5 pg) was denatured in formalobtained. A cold TGF-a cRNA sense strand was used as a positive dehyde at 600C for 15 min and blotted as described (26). The hybridization control.
filters were hybridized as mentioned above. The signals obtained were scanned densitometrically. TGF-u readings were correlated was isolated by guanidine isothiocyanate extraction and cesium with 28s readings. Results are expressed as mean -t SEM of four chloride centrifugation (25), measured spectrophotometrically at to five explant cultures (from four to five different fetuses). 260 nm, and stored at -20°C until use. From a few tissues (fetal Probes. A 925-bp EcoRI fragment of human TGF-a (28) and adrenal, brain, and placenta), polyadenylated RNA also was a 555-bp EcoRI fragment of human EGF (29) cDNA were isolated using oligo(dT) columns (Pharmacia, Uppsala, Sweden). subcloned into pGEM7(z) ribovectors (Promega Biotechnology, Fig. 3 . Northern blot analysis of TGF-a expression in human fetus. Total RNA (30 pg) from the human fetal GI tract and other tissues (2-5 pg polyadenylated RNA from brain, placenta, adrenals, and A431 cells) were subjected to electrophoresis and subsequently blotted onto a nylon filter and hybridized with a 32P-labeled TGF-a cRNA probe. The correct transcript size is shown on the right. Integrity of RNA samples was controlled with a 28s or a 7-actin (polyadenylated RNA samples) cDNA probe. RNA derived from A43 1 cells was used as a positive hybridization control for the TGF-a probe. . The correct size of the labeled probes was checked in a sequencing gel. TGF-a PCR fragments from human fetal decidua (I st trimester) and fetal duodenum (2nd trimester) were also subcloned into pGEM7(z) ribovectors as described (27).
[32P]-dCTP random prime-labeled (Oligolabeling Kit, Pharmacia, Uppsala, Sweden) 28s or ?-actin cDNA (31) were used to verify the integrity of the RNA and to equalize the amounts of loaded RNA.
For PCR Southern blots, a 32P-labeled 925-bp TGF cDNA probe, a 27-mer internal EGF oligoprobe (nucleotides 3440 to 3466 of human EGF precursor) (32), and a P-actin oligoprobe (nucleotides 3 12 to 338 of human 0-actin cDNA) (33) were used for hybridizations. Oligoprobes were 3'-end-labeled with [32P]-dCTP using terminal transferase (DuPont/New England Nuclear labeling system, NEP-100, Boston, MA).
Reverse transcription and PCR. One pg of total RNA from each tissue was used for cDNA synthesis as described previously (34). For a negative control, water was used instead of RNA. PCR was performed according to the instructions provided with the GeneAmp DNA Amplification Reagent Kit (Perkin-ElmerCetus, Nonvalk, CT). One pL of reverse transcription mixture was combined with 1 ) 5 pL of 10x PCR-reaction buffer; 2) 37 pL of water; 3) 4 pL of dNTP mixture (0.2 pM final concentration for each deoxynucleotide); 4) 50 pmol of antisense and sense strand primes each; and 5) 2.5 U of AmpliTaq (Perkin-ElmerCetus) enzyme. The reactions were heated to 95°C for 2 min and then immediately cycled (30 cycles: 94°C for 30 s for denaturation, 58°C for 30 s for annealing, and 72°C for 1 min 30 s for elongation) in a Hybaid thermal reactor (Teddington, UK).
The following oligonucleotide primers were synthesized: a 20-mer TGF-a sense primer (5'-CGCCCTGTTCGCTCTGGGTA-3') corresponds to nucleotides 58 to 77, and a 20-mer antisense primer (5'-CTGGCTGGCAGCCACCACGG-3') corresponds to nucleotides 300 to 319 (35). The expected size of the TGF-a PCR product is 262 bp. EGF 20-mer sense (5'-GACGCCTGTCTGAACCAGGA-3') and 20-mer antisense (5'-CGATAGCAGCTTCTGAGTCC-3') primers create a 368-bp fragment corresponding to nucleotides 326 1 to 3628 of the EGF precursor (32). P-Actin sense (5'-CCCAGGCACCAGGGCGT-GAT-3'; nucleotides 153 to 172) and antisense (5'-TCAAACAT-GATCTGGGTCAT-3'; nucleotides 396 to 415) primers create a 263-bp fragment (33). The P-actin PCR was done to verify the integrity of the reverse transcribed mRNA.
Ten-pL aliquots of the PCR reaction products were sizefractionated in 2% agarose gel (Pharmacia, Sweden). HaeIIIdigested pBR322/@XRF fragments were used as size markers. Southern transfer was done by capillary blotting the DNA to Hybond-N nailon membranes (Amersham). The membranes were hybridized with 32P-dCTP-labeled TGF-a cDNA, EGF, or @-actin oligoprobes.
RNase protection assay. Protection assay was performed as described (27). Briefly, 30 to 80 pg of fetal RNA samples were hybridized with 200 000 cpm of 32P-labeled EGF and TGF-a riboprobes. Transfer RNA was used as a negative control and cold sense strands as positive controls. After treatments with RNaseA (40 mg/L; Sigma Chemical Co., MO) and RNaseTl (375 000 U/L; Boehringer, Mannheim, Germany) and digestion with proteinase K (100 mg/L) and 0.5% SDS, the protected RNA-RNA duplexes were extracted with phenol and chloroform, precipitated with ethanol, and analyzed on denaturing 6% PAGE-urea gel. The EGF riboprobe contained 555-bp bases of EGF mRNA and 30 bases of the pGEM7(z) sequence. The TGFa riboprobe contained 270 bases of TGF-a mRNA and 40 bases of the vector sequence, respectively.
Immunohistochemistry. Paraformaldehyde-fixed cultured jejunum, ileum, and colon explants were embedded in paraffin.
Immunohistochemistry was performed using a Super Sensitive Multilink kit and a monoclonal EGF-R antibody (BioGenex, San Ramon, CA) (27). This antibody reacts with the 170-kD EGF-R transmembrane glycoprotein (obtained from A43 1 carcinoma cells). Briefly, the sections were incubated for I h with the antibody, washed twice in PBS-0.25% Triton X-100 (PBS-TX), and incubated with biotinylated anti-immunoglobulins for 20 min. The sections were then washed again in PBS-TX, and treated with AP-conjugated streptavidin for 20 min and with substrate solution for 25 min. Endogenic AP was blocked by including 10 mM levamisole (Sigma) and 25 mM phenylalanine in the substrate solution. Fast Red was used as a chromogen. EGF-R antibody was replaced by normal mouse serum for specificity controls. To exclude false-positive staining due to endogenous AP, the immunostaining was also performed with peroxidase-conjugated streptavidin (Dako, Copenhagen, Denmark) instead of AP. The results were the same with both enzyme conjugates. Before microscopic examination, the slides were counterstained with Mayer's hematoxylin. Western immunoblot analysis. Two-mL samples from d-5 and d-7 intestine cultures were pooled, concentrated 40-fold with Centricon 3 (Grace & Co, Beverly, MA), and mixed with 2X Laemmli buffer with P-mercaptoethanol. After 15% SDS-gel electrophoresis (36), the samples were electroblotted (250 mA for 1 h) to Hybond C-nitrocellulose paper (Amersham) using Bio-Rad Trans-Blot apparatus (37). Nonspecific binding was blocked by incubating the membrane overnight in 10% BSA-0.1% Tween 20 (Bio-Rad, Richmond, CA) in PBS. The membrane was incubated with the goat anti-human TGF-a (1: 15000 dilution, Biotope), washed thoroughly in 0.1 % Tween-PBS, and incubated with peroxidase-conjugated donkey anti-sheep IgG (Jackson, West Grove, PA). The immunoreaction was detected using the ECL system according to the manufacturer's instructions (Amersham). Recombinant TGF-a (Amgen) was used as a positive control. For specificity controls, staining was performed with preabsorbed antiserum (14 pM TGF-a). Immunoreactions were either abolished or reduced.
RESULTS
Expression of TGF-a mRNA in intestine. Samples of total
RNA from human fetal (15 to 20 wk of gestation) duodenum, Other positive tissues were submandibular salivary gland, pancreas, gallbladder, liver, adrenals, kidney, lungs, thyroid gland, brain (cerebellum, weakly), spinal cord, skin, testes, femur (weakly), and decidua from a 2nd-trimester placenta (Fig. 1B ). An RNase protection assay was performed using a TGF-a riboprobe obtained from a decidual TGF-a PCR fragment. Protected hybrids were seen in both the fractioned and the cultured intestine (Fig. 2) . A single band of 4.8 kb corresponding to TGF-a mRNA was also detected by Northern blotting; it was strongest in the duodenum (Fig. 3) . TGF-a mRNA was only faintly visible in cultured jejunal organ explants (data not shown). TGF-a expression was also detected with Northern blotting from submandibular salivary gland, gallbladder, pancreas, kidney, adrenal, brain, liver, and placenta (10 wk of gestation) (Fig. 3) . The integrity of the RNA samples was controlled by hybridization with a 28s or a y-actin cDNA probe (not shown). RNA for PCR, RNase protection, and Northern blot analysis derived from different fetuses.
Expression of E G F mRNA in intestine. An EGF-specific 367-bp PCR fragment was amplifiable from duodenum, jejunum, ileum, and colon. Specificity was verified by hybridizing the generated Southern blots with an internal oligoprobe (Fig. 4) . Other tissues positive in EGF PCR were skin, kidney, liver, submandibular salivary gland, pancreas, thyroid gland (not shown), and, faintly, femur (comprised also bone marrow; Fig.  4 ). The sensitivity of Northern blot analysis was insufficient to detect any EGF mRNA from the intestine. Using RNase protection assay, however, EGF transcripts could be located in duodenum, small intestine, and colon, respectively, corresponding to the PCR results (Fig. 5) .
Regulation of TGF-a mRNA by EGF and TGF-a in intestine organ cultures. To further elucidate the function of EGF and TGF-a in fetal gut, organ cultures were studied. Explants from the jejunum, ileum, and colon (five different fetuses of 15 to 19 wk of gestation) were grown in Leibowitz L-15 medium supplemented with EGF (100 gg/L) or TGF-a (100 pg/L) for 1 wk. The presence of immunoreactive EGF-R in the intestine was demonstrated by an MAb against the extracellular domain of the receptor. In the intact small and large intestine, EGF-R-like immunoreactivity was detected in the crypts, villi (being strongest in the apical region and in the brush border, although also in the basolateral region of the epithelial cells), capillary vessel walls, and in lamina propria. In the cultured jejunum, EGF-R-like immunoreactivity was localized to the goblet cells and epithelial cells of the villi and to the crypts (Fig. 6 ). In the cultured ileum and colon, the villous epithelium was only weakly positive. Endogenous AP was blocked during the staining procedure by levamisole and phenylalanine (38). For specificity controls, the antibody was replaced with normal mouse serum, and no staining was then seen. Furthermore, identical staining patterns were obtained when a peroxidase-conjugated rabbit anti-mouse antiserum was used instead of an AP-conjugated antiserum (not shown). This precluded the possibility that the intense staining would represent endogenous AP.
Because the amount of RNA obtained from the cultures was too low for Northern blot analysis, the regulation of TGF-CY mRNA was studied in a dot-blot system. In the jejunum, EGF up-regulated TGF-a mRNA by approximately 3-fold, but TGFa down-regulated its own mRNA by 40%. The ileum and colon did not respond to either growth factor (Fig. 7) . To study whether the TGF-a mRNA is translated to protein, Western blot analysis was performed from the concentrated culture media. No mature TGF-a peptide was detectable (apart from the exogenous TGFa), but precursor forms of approximately 30 kD and 60 to 68 kD were found (Fig. 8) . When an antiserum preabsorbed with excess TGF-a was used, these immunoreactive bands were abolished. The amount of protein in the control and EGFITGF-astimulated organ explants could not be equalized owing to limited material; therefore, no difference was seen between the control and stimulated cultures.
DISCUSSION
The present article reports the expression of EGF and TGF-a mRNA in the human fetal 2nd-trimester GI tract. TGF-a expression was strongest in the duodenum, gallbladder, pancreas, and submandibular salivary gland. It was expressed more abundantly in the intestine than EGF, because EGF mRNA was detectable only with the sensitive PCR and RNase protection assays, but TGF-a mRNA was also demonstrated by Northern blot analysis. TGF-a is synthesized during early murine development (lo), but from human fetuses there is little evidence of this (27). EGF mRNA has not been previously detected during fetal development, probably because of insensitivity of methods. Nevertheless, the present data reveal a low-level expression of EGF in the 2nd-trimester human fetal intestine. Thus, TGF-a appears to be the major EGF-like peptide in 15-to 20-wk-old human fetuses.
Human fetal jejunum and colon grow in organ culture (39, 40) . At the 18th wk of gestation, proliferating epithelial cells in the cultured and intact intestine are confined to the crypts. In the present study, the morphology of the explant cultures was preserved after 7 d in culture, and staining with hematoxylin was localized to the crypts (Fig. 7A) . Immunoreactive EGF-R was also strongly detected in the villi, crypts, and capillary vessel wall in both the intact and the cultured intestine ( Fig. 7B-C) . Furthermore, TGF-a mRNA was inducible with exogenous EGF. This agrees with previous results with adult human and animal cell cultures; namely, TGF-a mRNA was up-regulated by EGF and/or TGF-a (5 to 100 pg/L) in most short-term (2-to 48-h) stimulation experiments with rat intestinal epithelial cells (22), regenerating liver (41), carcinoma cells from human pancreas (42) , and cultured human keratinocytes (43) . These effects were transient, usually declining within 24 h. The mechanism behind the TGF-a mRNA rise may be increased transcription (44) . In well-differentiated quiescent colon carcinoma cells, EGF also upregulated TGF-a mRNA, but was without effect on TGF-a synthesis in poorly differentiated cells (21, 45) . In the present study, exogenous TGF-a reduced its own mRNA expression by 40%. This differs from the above-mentioned reports on adult and malignant cells, probably owing to the longer observation time used in the present experiments. Why EGF and TGF-a have different effects on TGF-a mRNA remains unclear. Recently, TGF-CY binding was found to be increased in a pancreatic cancer cell line at alkaline pH. At neutral pH, TGF-a binding was markedly less than EGF binding (46) . Therefore, EGF and TGF-a may regulate signal transduction pathways differently in different cell types through dissimilar interactions with the receptor. In addition, the intestine may respond differently to different doses of EGF and TGF-a. Unfortunately, the limited material available did not allow detailed dose-response studies.
Surprisingly, in the ileum and colon, TGF-a mRNA synthesis did not change after stimulations with EGF and TGF-a. According to our Northern blot results, there are no substantial differences in TGF-a expression between the intact jejunum, ileum, and colon. However, we found previously that the ileum and colon contain less TGF-a-like immunoreactivity than the duodenum and jejunum (6) . Furthermore, it has been shown that, in fetal rhesus monkey, the growth-promoting activity of EGF is largely restricted to the upper intestine ( 1 3). Therefore, the 2nd-trimester ileum and colon may require higher concentrations of EGFITGF-a than the jejunum to obtain similar effects. This could be due to a difference in receptor density. In autoradiographic studies, the human fetal colon exhibited more EGFbinding capacity than the small intestine (19) . However, my unpublished results show that the EGF-R immunoreactivity is rather equally distributed between jejunum, ileum, and colon (two to three fetuses). In the present study, a strong EGF-R immunoreaction is located both in the crypts and in the brush border. The mapping of EGF-R to the apical surface is contrary to the '''1-EGF binding study of M6nard and Pothier (47) . Methodologic differences could explain the partially different results. Furthermore, the absence of labeled EGF in the villi observed by Mirnard and Pothier could also result from the already occupied EGF receptors by endogenous TGF-a or EGF.
EGF and TGF-a are both mitogens. In the human fetal jejunum and colon, EGF stimulates proliferation and differentiation (1 7, 18). EGF also promotes proliferation of the small intestinal mucosa in neonatal microvillous atrophy (48) . The present demonstration of expression of both TGF-a and EGF in the human fetal GI tract further implies an important role for these peptides in the developing gut. Introduction of EGF-like peptides into the treatment of very premature newborns may in the future help to prevent GI problems caused by the immature intestines of these babies.
